Cytokinetics EVP exercises options and sells 2,000 shares on 10/07/2025

Rhea-AI Filing Summary

Insider exercise and sale by Cytokinetics EVP R&D. On 10/07/2025 Dr. Malik Fady Ibraham exercised a non‑qualified stock option to acquire $0.00 priced shares (2,000 shares) at an exercise price of $10.60 and simultaneously sold 2,000 shares at $60.56. Following these transactions his reported beneficial ownership is 140,610 shares.

Positive

• Option exercise executed: 2,000 shares acquired at $10.60
• Immediate liquidity realized: 2,000 shares sold at $60.56
• Beneficial ownership maintained: reported holding of 140,610 shares after transactions

Negative

• None.

Insights

Corporate Insider Transactions Analyst

TL;DR: EVP exercised options and sold identical share amount the same day, leaving reported ownership at 140,610 shares.

The filing shows a non‑qualified stock option with an exercise price of $10.60 was exercised for 2,000 shares on 10/07/2025. The same day an equal number of shares (2,000) were sold at $60.56, and reported beneficial ownership after the transactions is 140,610 shares.

This pattern is a common mechanic for option exercise with immediate sale to cover exercise taxes or monetize gains. Watch ongoing Form 4s for changes to the 10/07/2025 pattern or additional sales within the next few reporting cycles.

Insider Trade Summary

Exercise and Sale: 2,000 shares ($100K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 2,000 shs ($121K)

Approx. gross sale proceeds $121K

Approx. exercise cost $21K

Approx. pre-tax spread $100K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	2,000	$0.00	$0.00
Exercise	Common Stock	2,000	$10.60	$21K
Sale	Common Stock	2,000	$60.56	$121K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 3,105 shares (Direct); Common Stock — 140,610 shares (Direct)

FAQ

What did CYTK insider Dr. Malik Ibraham do on 10/07/2025?

He exercised a non‑qualified stock option to acquire 2,000 shares at an exercise price of $10.60 and sold 2,000 shares at $60.56 on 10/07/2025.

How many CYTK shares does Dr. Malik Ibraham beneficially own after the reported transactions?

He reports beneficial ownership of 140,610 shares following the transactions.

What type of option was exercised by the reporting person?

A non‑qualified stock option with an exercise price of $10.60 was exercised for 2,000 shares.

At what price were the shares sold on 10/07/2025?

The sale price reported for the 2,000 shares sold was $60.56 per share.

Is the filing a single‑person Form 4 or a group filing?

The Form 4 was filed by a single reporting person (one reporting person).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/07/2025 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/07/2025		M		2,000	A	$10.6	142,610	D
Common Stock	10/07/2025		S		2,000	D	$60.56	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	10/07/2025		M			2,000	03/28/2017	02/28/2027	Common Stock	2,000	$0	3,105	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.